Innogenetics wins patent dispute


Brussels – Belgian biotech group Innogenetics welcomed a ruling by a US court, which decided that Abbott Laboratories may no longer sell products that infringe on an Innogenetics patent, but also upheld an earlier court’s decision that the infringement was not willful. The US District Court for the Western District of Wisconsin also prohibited Abbott from exporting components of the infringing products. In September 2006, a jury found Abbott had infringed Innogenetics’ US patent for a method of genotyping HCV (hepatitis C virus) and awarded Innogenetics US $7m in damages. “We have every reason to be confident”, said Frank Morich, CEO of Innogenetics at a news conference, stressing that the group already has partnerships with Bayer AG and Roche to use the HCV genotyping patents involved. The cost of the legal dispute weighed on the group’s first half results, but Morich says “the main bulk of the costs have been digested” and expects the impact to be much less significant in the second half of the year. Innogenetics began litigation procedures against Abbott Laboratories in September of 2005. After the end of the current ruling, Frank Morich left Innogenetics and joined Berlin-based aptamer company NOXXON AG.



Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...



Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...



Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...



Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...



Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...



Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...



Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...



Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...



Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues